Immunic Statistics
Total Valuation
Immunic has a market cap or net worth of $111.01 million. The enterprise value is -$20.31 million.
Important Dates
The last earnings date was Friday, November 13, 2026, before market open.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunic has 15.88 million shares outstanding. The number of shares has increased by 155.05% in one year.
| Current Share Class | 15.88M |
| Shares Outstanding | 15.88M |
| Shares Change (YoY) | +155.05% |
| Shares Change (QoQ) | +0.67% |
| Owned by Insiders (%) | 0.83% |
| Owned by Institutions (%) | 60.14% |
| Float | 12.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.06 |
| P/TBV Ratio | 1.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.28 |
| Quick Ratio | 4.20 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -223.18% and return on invested capital (ROIC) is -145.24%.
| Return on Equity (ROE) | -223.18% |
| Return on Assets (ROA) | -144.86% |
| Return on Invested Capital (ROIC) | -145.24% |
| Return on Capital Employed (ROCE) | -128.97% |
| Weighted Average Cost of Capital (WACC) | 12.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.28M |
| Employee Count | 100 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.00% in the last 52 weeks. The beta is 1.48, so Immunic's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -2.00% |
| 50-Day Moving Average | 8.20 |
| 200-Day Moving Average | 11.59 |
| Relative Strength Index (RSI) | 38.65 |
| Average Volume (20 Days) | 233,664 |
Short Selling Information
The latest short interest is 1.95 million, so 12.28% of the outstanding shares have been sold short.
| Short Interest | 1.95M |
| Short Previous Month | 1.86M |
| Short % of Shares Out | 12.28% |
| Short % of Float | 16.17% |
| Short Ratio (days to cover) | 4.83 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -135.26M |
| Pretax Income | -128.30M |
| Net Income | -128.30M |
| EBITDA | -135.11M |
| EBIT | -135.26M |
| Earnings Per Share (EPS) | -$3.80 |
Full Income Statement Balance Sheet
The company has $131.96 million in cash and $646,000 in debt, with a net cash position of $131.32 million or $8.27 per share.
| Cash & Cash Equivalents | 131.96M |
| Total Debt | 646,000 |
| Net Cash | 131.32M |
| Net Cash Per Share | $8.27 |
| Equity (Book Value) | 104.47M |
| Book Value Per Share | 6.58 |
| Working Capital | 103.54M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$95.97 million and capital expenditures -$366,000, giving a free cash flow of -$96.34 million.
| Operating Cash Flow | -95.97M |
| Capital Expenditures | -366,000 |
| Depreciation & Amortization | 147,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -96.34M |
| FCF Per Share | -$6.07 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunic does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -155.05% |
| Shareholder Yield | -155.05% |
| Earnings Yield | -54.40% |
| FCF Yield | -86.78% |
Analyst Forecast
The average price target for Immunic is $42.55, which is 508.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $42.55 |
| Price Target Difference | 508.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on April 27, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 27, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |